Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shilo Lefresne

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
BMJ Open|July 5, 2024
Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET CollaborationKristy P Robledo, Shilo Lefresne, Yu Yang Soon, et al.
International Journal of Radiation Oncology, Biology, Physics|January 14, 2024
Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 TrialSarah Baker, Linden Lechner, Mitchell Liu, et al.
International Journal of Radiation Oncology, Biology, Physics|August 21, 2024
Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP TrialDevin Schellenberg, Zsolt Gabos, Adele Duimering, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2026
Osimertinib and stereotactic radiosurgery for brain metastases in EGFR mutated lung cancer - The STARLET joint analysis of OUTRUN and LUOSICNS randomised trialsChee Khoon Lee, Shilo Lefresne, Yu Yang Soon, et al.
BMC Cancer|February 3, 2024
Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMETRobert Olson, Hadassah Abraham, Curtis Leclerc, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
BMJ Open|July 5, 2024
Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+osimertinib compared to osimertinib alone: the STARLET CollaborationKristy P Robledo, Shilo Lefresne, Yu Yang Soon, et al.
International Journal of Radiation Oncology, Biology, Physics|January 14, 2024
Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 TrialSarah Baker, Linden Lechner, Mitchell Liu, et al.
International Journal of Radiation Oncology, Biology, Physics|August 21, 2024
Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP TrialDevin Schellenberg, Zsolt Gabos, Adele Duimering, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 14, 2026
Osimertinib and stereotactic radiosurgery for brain metastases in EGFR mutated lung cancer - The STARLET joint analysis of OUTRUN and LUOSICNS randomised trialsChee Khoon Lee, Shilo Lefresne, Yu Yang Soon, et al.
BMC Cancer|February 3, 2024
Single vs. multiple fraction non-inferiority trial of stereotactic ablative radiotherapy for the comprehensive treatment of oligo-metastases/progression: SIMPLIFY-SABR-COMETRobert Olson, Hadassah Abraham, Curtis Leclerc, et al.
Pageof 4